Long-acting injectables may be better than daily pills for people with adherence challenges
Poor design makes it a battle to get young children with HIV to take their medicine
Too many older people with HIV taking medicines they may not need
Cabotegravir levels lower than trials in real-world study, but no increase in viral rebound
Dolutegravir-based triple therapy effectively suppresses HIV-2 viral load in small study
Multiple strategies needed to reduce disengagement from HIV care in Uganda
People with HIV still running out of treatment options – not always because of resistance
DoxyPEP did not reduce STIs among women, probably due to low adherence
Oral PrEP can work just as well for women as men, modelling studies conclude
